SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently under pressure as investors react to a combination of geopolitical tensions and mounting concerns over the company's aggressive spending on AI infrastructure. The community is actively debating the stock's future, with many users speculating on upcoming layoff announcements while others view the current price action as a buying opportunity for long-term holders.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital is trending following a strategic move to repurchase $1 billion in debt at a significant discount, funded by the sale of Bitcoin. While the community is actively debating the merits of this balance sheet cleanup versus the reduction of their core Bitcoin holdings, investors remain fixated on the potential for a short squeeze as the company shifts its focus toward AI infrastructure and high-performance computing.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin shares are experiencing extreme volatility and intense retail debate as traders weigh potential AI-driven growth against ongoing concerns regarding institutional competition and short-seller reports. While bulls cite the company's strong ad-tech performance and potential for a massive short squeeze as catalysts for a rally, bears remain skeptical, highlighting insider selling and broader market headwinds as reasons for caution.

Maase, Inc. engages in the provision of intelligent technology-driven family and enterprise services. It operates through the following business segments: Insurance Agency and Wealth Management. The Insurance Agency segment involves in providing agency services for distributing life and non-life insurance products on behalf of insurance companies. The Wealth Management segment offers financial advisory, investment planning, and asset management services for individuals, families, and corporate clients, utilizing data-driven insights and digital platforms to optimize financial outcomes. The company was founded by Hai Feng Yu on August 6, 2018, and is headquartered in Guangzhou, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is generating significant community interest as it transitions from a niche hardware provider into a broader energy infrastructure player through a strategic acquisition of AI-driven biotech and resource assets. Investors are actively debating whether this pivot into high-value sectors like AI-enabled energy storage and healthcare provides a scalable foundation for future growth or reflects standard small-cap volatility.

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals is trending as investors position for the March 28 PDUFA date for KRESLADI, with high community optimism driven by strong trial data and a potential Priority Review Voucher. While the stock has seen increased option volume and institutional accumulation, community discourse remains focused on the company's manufacturing progress and the high-stakes binary nature of the upcoming regulatory decision.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is experiencing intense volatility and downward pressure as investors react to a short report alleging channel stuffing and accounting discrepancies, leading to widespread community debate over the company's integrity versus its long-term growth potential. While management has dismissed the allegations as speculative and inaccurate, shareholders remain divided, with many actively calling for a more detailed rebuttal and immediate action to restore market confidence.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is experiencing significant market volatility following a recent stock offering and investor reaction to Phase 1 data for its obesity candidate, WVE-007. While the community remains sharply divided, active discussions are focused on whether the sell-off represents a temporary overreaction to financing or a broader reassessment of the drug's competitive positioning against established GLP-1 treatments.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is trending due to a surge in momentum surrounding potential short squeeze dynamics, further fueled by news of Fannie Mae exploring crypto-backed mortgages. The community is actively discussing the company's strategic partnerships with Coinbase and Fannie Mae, alongside optimism regarding insider buying and the potential for a technical breakout.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant investor interest as a proxy for the upcoming SpaceX IPO, with community members actively comparing its concentrated exposure in SpaceX and Anthropic to other high-valuation funds. Traders are closely monitoring volume and potential short-squeeze dynamics, debating whether the current price represents an attractive entry relative to net asset value or if it is currently overextended.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak Sciences is trending as shares rally following positive topline results from the Phase 3 GLOW2 study of Zenkuda for diabetic retinopathy, with investors actively discussing the potential for a short squeeze given high short interest. The community is heavily focused on the drug's demonstrated superiority over placebo, fueling speculation about the company's prospects as an acquisition target.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


fyptt

Fyptt